Search for: "Regeneron"
Results 1 - 20
of 220
Sort by Relevance
|
Sort by Date
1 May 2024, 6:31 am
Westchester is home to companies much as Mastercard, Pepsi, IBM and Regeneron. [read post]
24 Apr 2024, 4:52 am
(Regeneron) under the False Claims Act (FCA). [read post]
17 Apr 2024, 8:47 am
The United States announced that it has intervened in a False Claims Act case against New York-based… The post DOJ Files Second Qui Tam Lawsuit Against Regeneron Pharmaceuticals appeared first on TZ Legal - Fraud Fighters. [read post]
16 Apr 2024, 8:42 am
The Regeneron/Ocular brief states that the problem is not limited to the courts, and that mandated clinicaltrials.gov disclosures are now being used as evidence of obviousness in IPR proceedings and during patent examination. [read post]
10 Apr 2024, 5:08 pm
(Regeneron), a New York-based pharmaceutical company. [read post]
29 Mar 2024, 4:56 pm
US appeals court revives Regeneron’s antitrust lawsuit against Novartis. [read post]
22 Mar 2024, 1:27 pm
" Regeneron Pharmaceuticals sues Novartis over antitrust claims related to prescription medications used to treat the overproduction of vascular endothelial growth factor (VEGF). [read post]
27 Dec 2023, 5:51 am
The plot gets more interesting, however, in that it now appears that in the local division action co-defendants Sanofi and Regeneron have filed a common defence, but only Regeneron has filed a revocation counterclaim meaning – entirely coincidentally I’m sure – there is no identity of parties and issues as between the local and central divisions, leaving the possibility that both cases can run in parallel. [read post]
22 Dec 2023, 5:29 am
Gold Standard test for novelty reigns supreme, even for subranges (T 1688/20)Make no bones about it: The "credibility test" has no place in the novelty assessment of second medical use claims (T 0558/20)Defining what the invention is not can be as important as defining what the invention is (T 0273/22, Chimeric antibodies/REGENERON)Unambiguous disclosure without patent profanity (T 2171/21)Artificial intelligence and the rise of LLMsThe biggest technological event this year… [read post]
20 Dec 2023, 1:28 am
(if selecting from convergent lists) (T 1621/16) (March 2020)Adding matter by cherry-picking from separate embodiments: Philip Morris v BAT ([2023] EWHC 2616 (Pat)) (Oct 2023)Defining what the invention is not can be as important as defining what the invention is (T 0273/22, Chimeric antibodies/REGENERON) (Nov 2023)The criteria for the novelty and inventive step of pharmaceutical selection inventions (T 1356/21) (Dec 2023)Image credit: DALLE-3 [read post]
23 Nov 2023, 6:58 am
Below, you’ll find a weekly summary of what happened on the IPKat recently, while competent authorities were busy handing down interesting decisions in IP-related cases.Image: shutterstock.comTrade marks Kevin Bercimuelle-Chamot reviewed a recent decision of the EUIPO’s First Board of Appeal concerning an opposition to the registration as an EU word mark of “miababy”, grounded on its alleged confusing similarity with the earlier trade mark "ia BABY… [read post]
17 Nov 2023, 6:00 am
This is the first of a new series of monthly posts on the UPC from Bristows, in which our UPC experts will be providing their commentary and insights on the development and themes arising from the cases being brought in the UPC. [read post]
13 Nov 2023, 1:28 am
A recent Board of Appeal decision T 0273/22 related to a patent in the same family as that of the landmark UK Supreme Court decision Regeneron v Kymab. [read post]
3 Nov 2023, 7:15 am
The starting point for Mellor J’s analysis was Kitchin LJ’s judgment in Regeneron v Genentech [2013] EWCA Civ 93. [read post]
28 Sep 2023, 10:09 am
By Nikhil Chaudhry and Reshma Ramachandran Earlier this month, the Department of Health and Human Services announced that it had successfully included a reasonable pricing provision in a $326M investment contract with Regeneron for development of a next generation monoclonal antibody therapy for COVID-19. [read post]
26 Aug 2023, 9:16 am
Settlement As was pointed out in an article of EIP Amar, ‘many of the parties involved in (…) initial infringement actions are pairings familiar from litigation already being fought in UK, Germany or US, such as Edwards Life Sciences against Meril, Ocado against Autostore and Amgen against Sanofi / Regeneron’. [read post]
31 Jul 2023, 1:18 am
Further readingKymab caught the mouse as sufficiency strengthened by UK Supreme Court in Regeneron battle ([2020] UKSC 27) (June 2020)Shining the light on insufficiency (T 1285/15) (August 2020)Illumina v MGI Part 1: Mr Justice Birss on sufficiency, DNA sequencing and chocolate teapots (Feb 2021)US Supreme Court decision in Amgen v Sanofi: The European Perspective (May 2023)Sufficiency of broad functional genus and first medical use claims in Europe (T 0424/21) (Oct… [read post]
25 Jul 2023, 9:05 pm
The briefs provide arguments separately on the purported scientific (by several noted scientists*) and legal (by Regeneron Pharmaceuticals, Inc.) errors the Board made in arriving at its decision. [read post]
10 Jun 2023, 4:02 pm
In Regeneron, the applicant had a good idea. [read post]
9 Jun 2023, 8:36 am
The Federal Trade Commission (FTC) recently announced that it would sue to block Amgen’s proposed $27.8 billion acquisition of Horizon Therapeutics. [read post]
